Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Employment agrmnt
Acq. announced
Director departure
Inv. presentation
Appointed CFO
Quarterly results
Appointed COO
Appointed director
BIOMET INC (BMET) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/12/2011 8-K Form 8-K - Current report
01/06/2011 8-K Form 8-K - Current report
10/12/2010 8-K Form 8-K - Current report
07/13/2010 8-K Form 8-K - Current report
04/14/2010 8-K Form 8-K - Current report
01/06/2010 8-K Quarterly results
Docs: "BIOMET ANNOUNCES FINANCIAL RESULTS FOR SECOND QUARTER OF FISCAL YEAR 2010 WARSAW, Ind., January 6, 2010 - Biomet, Inc. announced today financial results for its second fiscal quarter ended November 30, 2009."
10/09/2009 8-K Quarterly results
Docs: "PRESS RELEASE ISSUED OCTOBER 9, 2009."
07/15/2009 8-K Quarterly results
Docs: "Fourth Quarter Financial Results"
04/14/2009 8-K Quarterly results
Docs: "BIOMET ANNOUNCES FINANCIAL RESULTS FOR THIRD QUARTER OF FISCAL YEAR 2009 WARSAW, Ind., April 14, 2009 - Biomet, Inc. announced today financial results for its third fiscal quarter ended February 28, 2009. The Company previously announced net sales results for the fiscal third quarter and nine month year-to-date period in its press release issued April 8, 2009, which is posted on Biomet's website: www.biomet.com in the Investors Section. Net sales increased 2% to $615.0 million during the third quarter of fiscal year 2009, compared to $603.1 million for the third quarter of fiscal year 2008. Excluding the impact of foreign currency, net sales increased 7%. During the third quarter of fiscal year 2009, the Company recorded $572.0 million of special items , including a preliminary goodwill an..."
01/13/2009 8-K Quarterly results
Docs: "BIOMET ANNOUNCES FINANCIAL RESULTS FOR SECOND QUARTER OF FISCAL YEAR 2009 WARSAW, Ind., January 13, 2009 - Biomet, Inc. announced today financial results for its second fiscal quarter ended November 30, 2008."
10/10/2008 8-K Quarterly results
Docs: "BIOMET ANNOUNCES FINANCIAL RESULTS FOR FIRST QUARTER OF FISCAL YEAR 2009 WARSAW, Ind., October 10, 2008 - Biomet, Inc. announced today financial results for its first fiscal quarter ended August 31, 2008."
07/11/2008 8-K Quarterly results
Docs: "Fourth Quarter Results",
"Other Financial Information",
"Other Sales Information"
07/09/2007 8-K Quarterly results
Docs: "Fourth Quarter Results"
10/10/2006 8-K Quarterly results
Docs: "BIOMET ANNOUNCES RECORD FIRST QUARTER RESULTS Biomet, Inc. today reported record sales and earnings results for its first quarter ended August 31, 2006. Net sales increased 5% to $508,161,000. Operating income increased 2% to $155,043,000 from $151,410,000, and on an adjusted basis increased 7% to $159,269,000. Net income increased 2% to $102,830,000 from $100,299,000. and increased 6% on an adjusted basis to $106,815,000. Diluted earnings per share increased 5% to $0.42 from $0.40, and increased 10% on an adjusted basis to $0.44. Reported earnings per share for the first quarter of fiscal year 2007 includes a $.02 per share impact related to SFAS 123 Share-Based Payment. Effective June 1, 2006, the Company adopted this new accounting standard using the modified-prospective method. In acco..."
09/20/2006 8-K Quarterly results
Docs: "BIOMET ANNOUNCES RECORD FIRST QUARTER RESULTS Biomet, Inc. today reported record sales and earnings results for its first quarter ended August 31, 2006. Net sales increased 5% to $508,161,000. Operating income increased 2% to $155,043,000 from $151,410,000, and on an adjusted basis increased 7% to $159,269,000. Net income increased 2% to $102,830,000 from $100,299,000. and increased 6% on an adjusted basis to $106,815,000. Diluted earnings per share increased 5% to $0.42 from $0.40, and increased 10% on an adjusted basis to $0.44. Reported earnings per share for the first quarter of fiscal year 2007 includes a $.02 per share impact related to SFAS 123 Share-Based Payment. Effective June 1, 2006, the Company adopted this new accounting standard using the modified-prospective method. In acco..."
06/28/2006 8-K Quarterly results
Docs: "BIOMET ANNOUNCES FOURTH QUARTER AND FISCAL YEAR-END RESULTS, AND CASH DIVIDEND Biomet, Inc. announced today that its Board of Directors declared a cash dividend of $0.30 per share, payable July 21, 2006, to shareholders of record at the close of business on July 14, 2006. Interim President and Chief Executive Officer Daniel P. Hann stated, “The declaration of this dividend is in response to the Company’ s record financial performance during fiscal year 2006 and our anticipated results during fiscal year 2007.” During the fourth quarter of fiscal year 2006, net sales increased 7% to $539,892,000. Operating income decreased 5% to $147,601,000 from $155,734,000 and increased 5%, on an adjusted basis, to $166,501,000 from $158,178,000. Net income decreased 5% to $98,502,000 from $103,200,000 a..."
03/21/2006 8-K Quarterly results
Docs: "BIOMET ANNOUNCES RECORD THIRD QUARTER RESULTS Biomet, Inc. reports record sales and earnings results today for its third quarter ended February 28, 2006. Net sales increased 5% to $506,254,000. Operating income increased 9% to $156,993,000 from $144,270,000 and increased 4%, on an adjusted basis, from $151,672,000. Net income increased 10% to $106,065,000 from $96,784,000 and increased 4%, as adjusted, from $101,615,000. Diluted earnings per share increased 13% to $0.43 from $0.38 and increased 8%, on an adjusted basis, from $0.40. President and Chief Executive Officer Dane A. Miller, Ph.D., stated, “Biomet’ s record results during the third quarter of fiscal year 2006 are attributable to continued solid sales growth for orthopedic reconstructive devices, dental reconstructive implants and..."
12/21/2005 8-K Quarterly results
Docs: "BIOMET, INC. RESULTS FOR THE QUARTERS ENDED NOVEMBER 30 Three Months Ended Six Months Ended 2005 2004 2005 2004 Net Sales $494,690 $456,674 $979,593 $894,834 Cost of Sales 139,611 123,713 274,106 242,683 Cost of Sales, impact of inventory step-up -- 7,402 -- 14,404 Gross Profit 355,079 325,559 705,487 637,747 S, G, & A 181,453 166,305 359,635 326,765 R & D 21,303 19,606 42,119 38,082 In-process research and development -- -- -- 26,020 Operating Income 152,323 139,648 303,733 246,880 Other Income , Net 244 313 Income Before Taxes And Minority Interest 152,078 139,892 304,046 246,396 Income Taxes 50,800 51,264 102,469 99,767 Income Taxes related to inventory step-up -- -- Net Income 101,278 91,199 201,577 151,632 Earnings per Share Basic .41 .36 .81 .60 Diluted .41 .36 .81 .59 Basic Shares O..."
09/21/2005 8-K Quarterly results
Docs: "BIOMET ANNOUNCES RECORD FIRST QUARTER RESULTS Biomet, Inc. today reported record sales and earnings results for its first quarter ended August 31, 2005. Net sales increased 11% to $484,903,000. Operating income increased 41% to $151,410,000 from $107,232,000 and increased 8%, on an adjusted basis, from $140,254,000. Net income increased 66% to $100,299,000 from $60,433,000 and increased 10%, as adjusted, from $91,023,000. Diluted earnings per share increased 67% to $0.40 from $0.24 and increased 11%, on an adjusted basis, from $0.36. The Company's 2004 reported results reflect the acquisition of Merck KGaA's interest in the Biomet Merck joint venture on March 19, 2004, as well as the acquisition of Interpore International, Inc. on June 18, 2004. Adjusted results for last year, which are no..."
06/30/2005 8-K Quarterly results
Docs: "BIOMET ANNOUNCES RECORD FOURTH QUARTER AND FISCAL YEAR-END RESULTS, CASH DIVIDEND AND EXPANSION OF ITS SHARE REPURCHASE PROGRAM Biomet, Inc. announced today that its Board of Directors declared a cash dividend of $0.25 per share, payable July 22, 2005, to shareholders of record at the close of business on July 15, 2005. The Board also authorized the repurchase of 2.5 million shares of Biomet's outstanding Common Shares to be automatically purchased daily in equal increments over the next twelve months, irrespective of market conditions. This is in addition to the March 2005 authorization to repurchase up to an additional $100 million of the Company's outstanding Common Shares in open market or privately negotiated transactions, of which approximately $84 million is currently available. Sin..."
03/22/2005 8-K Quarterly results
Docs: "BIOMET, INC. - - QUARTERLY RESULTS FOR THE THREE AND NINE MONTHS ENDED FEBRUARY 28 Three Months Ended Nine Months Ended 2005 2004 2005 2004 Net Sales $482,023 $410,185 $1,376,857 $1,168,065 Cost of Sales 130,666 115,992 373,349 330,400 Cost of Sales, current period impact of inventory step-up 7,402 -- 21,806 -- Gross Profit 343,955 294,193 981,702 837,665 S, G, & A 179,224 145,712 505,989 414,773 R & D 20,461 15,892 58,543 46,450 In-process research and development -- -- 26,020 -- Operating Income 144,270 132,589 391,150 376,442 Other Income , Net 2,641 3,570 2,157 10,260 Income Before Taxes And Minority Interest 146,911 136,159 393,307 386,702 Income Taxes 52,698 47,430 152,465 134,659 Income Taxes related to inventory step-up -- -- Income Before Minority Interest 96,784 88,729 248,416 25..."
12/15/2004 8-K Quarterly results
Docs: "BIOMET, INC. - - QUARTERLY RESULTS FOR THE QUARTERS ENDED NOVEMBER 30 Three Months Ended 2004 Adjustments* As Adjusted* 2003 Net Sales $456,674 $456,674 $387,561 Cost of Sales 131,115 123,713 108,790 Gross Profit 325,559 7,402 332,961 278,771 S, G, & A 166,305 166,305 136,664 R & D 19,606 - 19,606 15,810 Operating Income 139,648 7,402 147,050 126,297 Other Income , Net 244 - 244 3,669 Income Before Taxes And Minority Interest 139,892 7,402 147,294 129,966 Income Taxes 48,693 2,571 51,264 45,250 Income Before Minority Interest 91,199 4,831 96,030 84,716 Minority Interest"
09/21/2004 8-K/A Quarterly results
Docs: "2004"
09/17/2004 8-K Quarterly results
Docs: "2004"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy